pentadecane-3,13-dione | 17745-38-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: pentadecane-3,13-dione
• CAS: 17745-38-9
• 化学式: C₁₅H₂₈O₂
• 分子量: 240.386
• InChiKey: XOAZHFSDWOTBAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  16-hydroxy-17-nitrooctadecane-3,13-dione 生成 pentadecane-3,13-dione
  参考文献：
  名称：

  PATERNE, MICHEL;DHAI;ROBERT;BROWN, ERIC, BULL. CHEM. SOC. JAP., 62,(1989) N, C. 1321-1324

  摘要：

  DOI：

文献信息

• Natural 2,6-Dialkyl-3-piperidinols. 9. Total Synthesis of (±)-Prosafrinine and¹³C NMR Studies of Some Analogous Compounds
  作者：Michel Paterne、Robert Dhal、Eric Brown

  DOI：10.1246/bcsj.62.1321

  日期：1989.4.15

  1,7-Dibromoheptane was used to alkylate both ketoesters 2 and 4 successively. Hydrolysis and decarboxylation of the resulting intermediate afforded the ethylenic diketone (6). Ozonolysis of the double bond of 6 gave the diketonic aldehyde (8). Alkaline condensation of nitroethane on the aldehydic carbonyl of the latter, followed by hydrogenation using a Pd–Pt catalyst, afforded 3-r-hydroxy-6-c-(10

  使用 1,7-二溴庚烷依次将酮酯 2 和 4 烷基化。所得中间体的水解和脱羧得到烯属二酮(6)。6 的双键臭氧分解得到二酮醛 (8)。硝基乙烷在后者的醛羰基上进行碱缩合，然后使用 Pd-Pt 催化剂氢化，得到 3-r-hydroxy-6-c-(10-oxododecyl)-2-c-methylpiperidine [(±)-prosafrinine ] (1a) 和 (±)-3-epirosafrinine (1b)。1a、1b 和一些类似物的结构由 13C NMR 研究证实。
• IAP BINDING COMPOUNDS
  申请人：Lundorf Mikkel Dybro

  公开号：US20110230419A1

  公开（公告）日：2011-09-22

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物或前药，其与凋亡抑制蛋白（IAPs）结合。本发明的化合物可用作诊断和治疗增生性疾病，例如癌症，促进增殖细胞的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供式(VI)或(VII)的聚合物化合物，其中包括至少两个式(I)的单体单位，或至少一个式(I)的单体单位和一个实体E。本发明还涉及包含上述化合物的药物组合物，以及在医学中使用上述化合物的用途。
• Reinheckel,H.; Gensike,R., Journal fur praktische Chemie (Leipzig 1954), 1968, vol. 37, p. 214 - 224
  作者：Reinheckel,H.、Gensike,R.

  DOI：——

  日期：——
• PATERNE, MICHEL;DHAI;ROBERT;BROWN, ERIC, BULL. CHEM. SOC. JAP., 62,(1989) N, C. 1321-1324
  作者：PATERNE, MICHEL、DHAI、ROBERT、BROWN, ERIC

  DOI：——

  日期：——